Javascript must be enabled to continue!
Abstract 1821: HER3 activation by MET contributes to trastuzumab resistance in HER2-positive breast cancer
View through CrossRef
Abstract
Background: Trastuzumab is a standard therapy for HER2-positive breast cancer patients. Majority of the patients treated with trastuzumab in metastatic disease experience relapse. MET has been reported as one possible candidate of trastuzumab resistance however, detailed mechanism is unclear.
Methods: Using panel of HER2-positive cell lines, pHER3 level was assessed with trastuzumab treatment by western blot. Co-immunoprecipitation and siRNA knockdown were used to assess the interaction between HER3 and MET.
Results: Phospho-HER3 as well as pAKT levels were decreased after trastuzumab treatment in trastuzumab sensitive cell lines, while there were no deactivation in the resistant cell lines. In the primary trastuzumab resistant cell lines, 5 of 6 cells expressed MET while only one of 4 cells expressed MET in the sensitive cell lines. BT474 cells were found to have increased MET level when the cells acquired resistance to trastuzumab. HCC1954 cells, MET overexpressing and primary trastuzumab cell line, were sensitized to trastuzumab when MET was knocked down. MET knockdown led to a decrease of phosphor-HER3 level in HCC1954, BT474, and BT474 trastuzumab resistant (BT-TR) cells. The paraffin-embedded tumor samples from BT474 xenograft treated with trastuzumab and HER2-positive breast cancer patients will be stained for MET expression to assess its prognostic and predictive values sin HER2 positive breast cancer.
Conclusion: MET may play a key role in maintaining HER3 phosphorylation during trastuzumab treatment and resistance in HER2 positive breast cancer.
Citation Format: Kenji Hashimoto, Valentine Macaulay, Anthony Kong. HER3 activation by MET contributes to trastuzumab resistance in HER2-positive breast cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1821. doi:10.1158/1538-7445.AM2014-1821
American Association for Cancer Research (AACR)
Title: Abstract 1821: HER3 activation by MET contributes to trastuzumab resistance in HER2-positive breast cancer
Description:
Abstract
Background: Trastuzumab is a standard therapy for HER2-positive breast cancer patients.
Majority of the patients treated with trastuzumab in metastatic disease experience relapse.
MET has been reported as one possible candidate of trastuzumab resistance however, detailed mechanism is unclear.
Methods: Using panel of HER2-positive cell lines, pHER3 level was assessed with trastuzumab treatment by western blot.
Co-immunoprecipitation and siRNA knockdown were used to assess the interaction between HER3 and MET.
Results: Phospho-HER3 as well as pAKT levels were decreased after trastuzumab treatment in trastuzumab sensitive cell lines, while there were no deactivation in the resistant cell lines.
In the primary trastuzumab resistant cell lines, 5 of 6 cells expressed MET while only one of 4 cells expressed MET in the sensitive cell lines.
BT474 cells were found to have increased MET level when the cells acquired resistance to trastuzumab.
HCC1954 cells, MET overexpressing and primary trastuzumab cell line, were sensitized to trastuzumab when MET was knocked down.
MET knockdown led to a decrease of phosphor-HER3 level in HCC1954, BT474, and BT474 trastuzumab resistant (BT-TR) cells.
The paraffin-embedded tumor samples from BT474 xenograft treated with trastuzumab and HER2-positive breast cancer patients will be stained for MET expression to assess its prognostic and predictive values sin HER2 positive breast cancer.
Conclusion: MET may play a key role in maintaining HER3 phosphorylation during trastuzumab treatment and resistance in HER2 positive breast cancer.
Citation Format: Kenji Hashimoto, Valentine Macaulay, Anthony Kong.
HER3 activation by MET contributes to trastuzumab resistance in HER2-positive breast cancer.
[abstract].
In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA.
Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1821.
doi:10.
1158/1538-7445.
AM2014-1821.
Related Results
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Abstract 1737: Overcoming trastuzumab resistance with the irreversible Pan-HER inhibitor neratinib
Abstract 1737: Overcoming trastuzumab resistance with the irreversible Pan-HER inhibitor neratinib
Abstract
Overexpression of HER2 is seen in 15-20% of breast cancer and is a predictor of poor prognosis. Trastuzumab, a monoclonal antibody to the ECD of the HER2 re...
Abstract 1530: Trastuzumab treatment induces ADAM17 and HER ligands in vivo
Abstract 1530: Trastuzumab treatment induces ADAM17 and HER ligands in vivo
Abstract
Anti-HER2 monoclonal antibody trastuzumab is used as treatment in patients with HER2 positive breast cancer. However, resistance inevitably occurs for all r...
Abstract PO5-07-11: Use of 64Cu-DOTA trastuzumab -PET to predict response to trastuzumab-deruxtecan (TDXd) in patients with metastatic disease to the brain: Study in Progress
Abstract PO5-07-11: Use of 64Cu-DOTA trastuzumab -PET to predict response to trastuzumab-deruxtecan (TDXd) in patients with metastatic disease to the brain: Study in Progress
Abstract
Background: We have utilized 64Cu-DOTA trastuzumab-PET imaging in patients with advanced breast cancer. In our experience, uptake on 64Cu-DOTA trastuzumab-P...
Abstract 2130A: Epigenetic silencing of TGFβ1, BCL6, KILLIN and CTSZ is related to trastuzumab resistance in HER2-positive breast cancer models
Abstract 2130A: Epigenetic silencing of TGFβ1, BCL6, KILLIN and CTSZ is related to trastuzumab resistance in HER2-positive breast cancer models
Abstract
Introduction: The major clinical problem for HER2 breast cancer target therapies is the acquisition of resistance. Trastuzumab has been used for the treatme...
Abstract P1-13-11: Optimal omission of anthracycline in adjuvant chemotherapy of HER2 positive breast cancer
Abstract P1-13-11: Optimal omission of anthracycline in adjuvant chemotherapy of HER2 positive breast cancer
Abstract
[Background]In adjuvant settings of HER2 positive cancer, trastuzumab has been shown to be effective in combination with anthracycline- based chemotherapy f...
Abstract 2271: bcl-2 expression in HER2-positive breast carcinoma subtypes
Abstract 2271: bcl-2 expression in HER2-positive breast carcinoma subtypes
Abstract
Background: HER2-positive breast cancers comprise 20-30% of all breast cancers; amplification of HER2 confers a poorer prognosis. While treatment with anti-...
Abstract 1836: Patient-derived xenograft (PDX) models expressing HER2 reflect clinical responses to targeted HER2 inhibition
Abstract 1836: Patient-derived xenograft (PDX) models expressing HER2 reflect clinical responses to targeted HER2 inhibition
Abstract
Background While HER2-directed agents are most often used for treating breast cancer, there is increasing evidence that these therapies may be of value in o...


